170 related articles for article (PubMed ID: 37410931)
1. WHAM-A Prospective Study of Weight and Body Composition After Risk-Reducing Bilateral Salpingo-oophorectomy.
Price SAL; Finch S; Krejany E; Jiang H; Kale A; Domchek S; Wrede D; Wark JD; Hickey M
J Clin Endocrinol Metab; 2023 Dec; 109(1):e397-e405. PubMed ID: 37410931
[TBL] [Abstract][Full Text] [Related]
2. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
[TBL] [Abstract][Full Text] [Related]
3. What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
Moss KM; Mishra GD; Krejany EO; Hickey M
Gynecol Oncol; 2022 Oct; 167(1):58-64. PubMed ID: 35933227
[TBL] [Abstract][Full Text] [Related]
4. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
5. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
[TBL] [Abstract][Full Text] [Related]
6. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Hickey M; Moss KM; Mishra GD; Krejany EO; Domchek SM; Wark JD; Trainer A; Wild RA
Gynecol Oncol; 2021 Jul; 162(1):88-96. PubMed ID: 33972087
[TBL] [Abstract][Full Text] [Related]
7. Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy.
Chan LN; Chen LM; Goldman M; Mak JS; Bauer DC; Boscardin J; Schembri M; Bae-Jump V; Friedman S; Jacoby VL
Obstet Gynecol; 2023 Jul; 142(1):160-169. PubMed ID: 37290104
[TBL] [Abstract][Full Text] [Related]
8. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
9. Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.
Chang H; Kamara D; Bresee C; Lester J; Cass I
Menopause; 2020 Dec; 28(4):354-359. PubMed ID: 33350669
[TBL] [Abstract][Full Text] [Related]
10. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
[TBL] [Abstract][Full Text] [Related]
11. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Hickey M; Moss KM; Brand A; Wrede CD; Domchek SM; Meiser B; Mishra GD; Joffe H
Gynecol Oncol; 2021 May; 161(2):527-534. PubMed ID: 33583580
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
[TBL] [Abstract][Full Text] [Related]
14. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study.
Terra L; Heemskerk-Gerritsen BAM; Beekman MJ; Engelhardt E; Mourits MJE; van Doorn HC; de Hullu JA; Mom CH; Slangen BFM; Gaarenstroom KN; van Beurden M; Roeters Van Lennep JE; van Dorst EBL; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Steensma AB; van Leeuwen FE
BJOG; 2024 Jan; 131(1):99-108. PubMed ID: 37394722
[TBL] [Abstract][Full Text] [Related]
15. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
16. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
[TBL] [Abstract][Full Text] [Related]
17. Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
Vermeulen RFM; van Beurden M; Gaarenstroom KN; Teunis T; Kieffer JM; Aaronson NK; Kenter GG; Korse CM
Climacteric; 2018 Dec; 21(6):574-580. PubMed ID: 30295077
[TBL] [Abstract][Full Text] [Related]
18. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
20. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
